More specifically, dabigatran is a direct inhibitor of thrombin (or factor IIa), a key factor in the coagulation process, therefore in the formation of blood clots (thrombi).
Therefore, dabigatran is used in cases where it is necessary to prevent the development of blood clots in the brain, lungs and legs, even in patients undergoing hip or knee surgery.
Dabigatran is administered orally. It is a drug belonging to the group of so-called New Oral Anticoagulants (NAO) and has been available in Europe since 2008.
In Italy, dabigatran is available in a "unique medicinal product - Pradaxa® - formulated in hard capsules to be taken orally. It is a medicine that, in order to be dispensed, requires a specific restrictive medical prescription, as it can be sold to the only on prescription from hospitals or specialists, however, it is classified as a class A drug, therefore its cost can be reimbursed by the National Health System (SSN).
